DXR - Daxor - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DXR is currently covered by 1 analysts with an average price target of $26.16. This is a potential upside of $15.75 (151.3%) from yesterday's end of day stock price of $10.41.

Daxor's activity chart (see below) currently has 1 price targets and 3 ratings on display. The stock rating distribution of DXR is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for DXR is $24.75, Lowest price target is $24.75, average price target is $24.75.

Most recent stock forecast was given by EDWARD WOO from ASCENDIANT on 09-Sep-2024. First documented stock forecast 16-May-2019.

Best performing analysts who are covering DXR - Daxor:

Edward Woo

Currently out of the existing stock ratings of DXR, 1 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Edward Woo (ASCENDIANT)

Buy

$24.75

$14.15 (133.49%)

$21

11 months 10 days ago
(09-Sep-2024)

0/2 (0%)

$15.75 (175.00%)

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is DXR (Daxor) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on DXR (Daxor) with a proven track record?

EDWARD WOO

Which analyst has the most public recommendations on DXR (Daxor)?

Edward Woo works at ASCENDIANT and has 1 price targets and 2 ratings on DXR

Which analyst is the currently most bullish on DXR (Daxor)?

Edward Woo with highest potential upside - $14.15

Daxor in the News

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The new Daxor BVA™ device...